6 trends tracked about this subject — the full history, oldest to newest below.
The FDA approves the first oral PCSK9 pill, Lipfendra, as Merck charts a long-term path.
Recent coverage examines how Lipfendra compares to traditional statins for lowering cholesterol.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Merck has achieved a regulatory milestone with the FDA approval of Lipfendra, the first-of-its-kind oral treatment for reducing cholesterol.
The FDA has approved Merck's Lipfendra, the first oral PCSK9 drug capable of lowering LDL cholesterol by nearly 60%.
The FDA has approved a first-of-its-kind daily oral pill from Merck designed to slash cholesterol levels.